Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: Relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features

Virchows Archiv

Volumn 437, Issue 1, 2000, Pages 25-30

  Horie, Satoshi ^a   Endo, Kanenori ^a   Kawasaki, Hironaka ^a   Terada, Tadashi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Clinicopathological correlation; Intrahepatic cholangiocarcinoma; Ki 67; MDM2; Tp53

Indexed keywords

KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; CLINICAL ARTICLE; CLINICAL FEATURE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; METASTASIS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSACTIVATION;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BLOTTING, WESTERN; CHOLANGIOCARCINOMA; GENE EXPRESSION; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033946629     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004280000201     Document Type: Article

References (57)

1. 1. Barak Y, Juven T, Haffner R, Oren M (1993) mdm2 expression is induced by wild type p53 activity. EMBO J 12:461-468
2. 2. Baunoch DA, Watkins LF, Tewari A, Reece MT, Adams L, Stack R, Brown A, Jones L, Christian D, Latif NA, Lawrence WD, Lane MA (1996) MDM2 overexpression in benign and malignant lesions of the human breast: association with ER expression. Int J Oncol 8:895-899
3. 3. Casey G, Lopez ME, Lamos JC, Plummer SJ, Arboleda MJ, Shaughnessy M, Karlan B, Slamon DJ (1996) DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 13:1971-1981
4. 4. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB (1994) Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A 91:2684-2688
5. 5. Cho Y, Gorina S, Jeffrey PD, Pavleetich NP (1994) Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumourigenic mutations. Science 265:346-355
6. 6. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan FM, Levine AJ (1994) Molecular abnormalities of mdm2 and p53 genes in adult soft tissue carcinoma. Cancer Res 54:794-799
7. 7. Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565-1569
8. 8. Gorgoulis VG, Zoumpourlis V, Rassidakis GZ, Karameris A, Rassidakis AN, Spandidos DA, Kittas C (1996) A molecular and immunohistochemical study of the mdm2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 180:129-137
9. 9. Gudas JM, Nguyen H, Klein RC, Katayose D, Seth P, Cowan KH (1995) Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1:71-80
10. 10. Habuchi T, Kinoshita H, Yamada H, Kakehi Y, Ogawa O, Wu W-J, Takahashi R, Sugiyama T, Yoshida O (1994) Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 86:1331-1335
11. 11. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane D (1991) p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 338:513
12. 12. Haupt Y, Barak Y, Oren M (1996) Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 15:1596-1606
13. 13. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299
14. 14. Hermanek P, Sobin LH (1992) TNM classification of malignant tumours, 4th edn. International Union Against Cancer. Springer, Berlin Heidelberg New York
15. 15. Higashiyama M, Doi O, Yokouchi K, Kasugai T, Ishiguro S, Takami K, Nakayama T, Nishisho I (1997) MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br J Cancer 75:1302-1308
16. 16. Ishak KG, Anthony PP, Sobin LH (1994) Histological typing of tumours of the liver, 2nd edn. WHO Series. Springer, Berlin Heidelberg New York
17. 17. Jiang M, Shao ZM, Wu J, Lu JS, Yu LM, Yuan JD, Han QX, Shen ZZ, Fontana JA (1997) p21/waf1/cip1 and mdm2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 74:529-534
18. 18. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Rescue of embryonic lethality in Mdm-2 deficient mice by absence of p53. Nature 378:206-208
19. 19. Juven-Gershon T, Shifman O, Unger T, Elkeles A, Haupt Y, Oren M (1998) The mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol 18:3974-3982
20. 20. Kondo S, Morimura T, Barnett GH, Kondo Y, Peterson JW, Kaakaji R, Takeuchi J, Toms SA, Liu J, Werbel B, Barna BP (1996) The transforming activities of MDM2 in cuitured neonatal rat astrocytes. Oncogene 13:1773-1779
21. 21. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303
22. 22. Kubbutat MH, Ludwig RL, Ashcroft M, Vousden KH (1998) Regulation of Mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 18:5690-5698
23. 23. Lane DP, Benchiniol S (1990) p53: oncogene or antioncogene? Genes Dev 4:1
24. 24. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53:2231-2234
25. 25. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C (1994) Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 86:1325-1330
26. 26. Liver Cancer Study Group of Japan (1992) The general rules for the clinical and pathological study of primary liver cancer (the 3rd edn). Kanehara Press, Tokyo
27. 27. Marchetti A, Buttitta F, Gilando S, Palma PD, Pellegrini S, Fina P, Douglioni C, Bevilacqua G, Barbareschi M (1995) mdm2 gene alterations and mdm2 protein expression in breast carcinoma. J Pathol 175:31-38
28. 28. Martin K, Trouche D, Hagemeler C, et al. (1995) Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 375:691-694
29. 29. Michalovitz D, Halevy O, Oren M (1990) Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant p53. Cell 62:671-680
30. 30. Molina P, Pellin A, Navarro S, Boix J, Carda C, Liombart-Bosch A (1999) Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance. Virchows Arch 435:586-605
31. 31. Momand J, Zambetti GP (1996) Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 12:2279-2289
32. 32. Momand J, Ambetti Gp, Olson DC, George D, Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245
33. 33. Naka T, Toyota N, Kaneko T, Kaibara N (1998) Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 18:555-564
34. 34. Nose H, Imazeki F, Ohto M, Omata M (1993) p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 72:355-360
35. 35. Ohashi K, Nakajima Y, Kanehiro H, Tsutsumi M, Taki J, Aomatsu Y, Yoshimura A, Ko S, Kin T, Yagura K (1995) Kiras mutations and p53 protein expression in intrahepatic cholangiocarcinoma: relation to gross tumor morphology. Gastroenterology 109:1612-1617
36. 36. Ohnishi H, Kawamura M, Hanada R, Kaneko Y, Tsunoda Y, Hongo T, Bessho F, Yokomori K, Hayashi Y (1996) Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Genes Chromosomes Cancer 15:187-190
37. 37. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-83
38. 38. Oliner JD, Piettenpol JA, Thiagalindam S, Gyuris J, Kinzler WK, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of suppressor p53. Nature 362:857-860
39. 39. Perry ME, Levine AJ (1994) p53 and mdm-2: interactions between tumor-suppressor gene and oncogene product. Mt Sinai J Med 61:291-299
40. 40. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Potes J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92:713-723
41. 41. Qiu SJ, Ye SL, Wu ZQ, Tang ZY, Liu YK (1998) The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 124:253-258
42. 42. Quesnel B, Preudhomme C, Fourneier J, Fenaux P, Peyrat JP (1994) MDM2 gene amplification in human breast cancer. Eur J Cancer 30:982-984
43. 43. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP (1993) Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 53:2736-2739
44. 44. Rizzi PM, Ryder SD, Portmann B, Ramage JK, Naoumov NV, Williams R (1996) p53 protein overexpression in cholangiocarcinoma arising in primary scleosing cholangitis. Gut 38:265-268
45. 45. Sheikh MS, Shao ZM, Hussain A, Fontana JA (1993) The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 53:3226-3228
46. 46. Shimada Y, Imamura M, Shibagaki I, Tanaka H, Miyahara T, Kato M, Ishizaki K (1997) Genetic alterations in patients with esophageal cancer with short-and long-term survival rates after curative esophagectomy. Ann Surg 226:162-168
47. 47. Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M (1999) Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 80:1281-1288
48. 48. Shrestha ML, Miyake H, Kikutsuji T, Tashiro S (1998) Prognostic significance of Ki-67 and p53 antigen expression in carcinomas of bile duct and gallbladder. J Med Invest 45:95-102
49. 49. Soslow RA, Altorki NK, Yang G, Xie D, Yang CS (1999) mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 12:580-586
50. 50. Terada T, Shimizu K, Izumi R, Nakanuma Y (1994) Methods in pathology. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 7:249-252
51. 51. Villumendasm R, Pezzella F, Gatter K, Algara P, Sanchez-Beato M, Martinez P, Martinez JC, Munoz K, Garcia P, Sanchez L, Kocialkowsky S, Campo E, Orradre JL, Piris MA (1997) p21 WAF1/CIP1 and mdm2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, mdm2-, p21-immunophenotype associated with missense p53 mutations. J Pathol 181:51-61
52. 52. Waber PG, Chen J, Nisen PD (1993) Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 53:6028-6030
53. 53. Wu X, Bayle JH, Olso D, Levine AJ (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev 7:1126-1132
54. 54. Wurl P, Meye A, Berger D, Lautenschlager C, Bache M, Holzhausen H-J, Schmidt H, Dralle H, Rath F-W, Taubert H (1998) Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma. Langenbecks Arch Surg 383:99-103
55. 55. Wurl P, Meye A, Schmidt H, Lautenschlager C, Kalthoff H, Rath F-W, Taubert H (1998) High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 16:1183-1185
56. 56. Xiao Z-X, Chen J, Levine AJ, et al. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698
57. 57. Zhang Y, Xiong Y, Yarbrough WG (1998) ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92:725-734